Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.

Cost of Revenue: A Tale of Two Biopharma Giants

In the competitive landscape of biopharmaceuticals, understanding cost structures is crucial. This analysis compares the cost of revenue for Sarepta Therapeutics, Inc. and Amneal Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Amneal Pharmaceuticals consistently reported higher costs, peaking at approximately $1.57 billion in 2023, a staggering 367% increase from 2014. In contrast, Sarepta Therapeutics, while showing growth, maintained a more modest cost structure, with a 60% increase over the same period, reaching around $150 million in 2023.

This disparity highlights differing business models and market strategies. Amneal's higher costs may reflect a broader product portfolio or aggressive market expansion, while Sarepta's leaner cost structure could indicate a focus on niche markets or innovative therapies. As the biopharma industry evolves, these insights offer a glimpse into the strategic decisions shaping the future of healthcare.